CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 7 enrolled
Drug / intervention
Photocil for Atopic Dermatitis +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01992172
NCT01992172N/ACompleted
CompareCT.gov

Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Atopic Dermatitis

Applied Biology, Inc.·interventional·Posted Nov 25, 2013·Updated Mar 25, 2016

In Brief

A clinical study evaluating Photocil for Atopic Dermatitis and Placebo - Sunscreen (SPF 2) for Atopic Dermatitis. Completed, enrolled 7 participants across 1 site.

Detailed Summary

Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight. Photocil is intended to help protect users from non-therapeutic Ultraviolet B (UVB) radiation while selectively passing wavelengths of light in the NB-UVB range with peak transmission of 308nm. The aim of the study is to assess the safety and efficacy of Photocil in the treatment of atopic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 25, 2013
Enrollment StartAug 1, 2013
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.6 years ago

Interventions

Photocil for Atopic Dermatitisdrug

Photocil for Atopic Dermatitis

Placebo - Sunscreen (SPF 2)other

Placebo - Sunscreen (SPF 2)